Barrett L, Mellor R, Ritter A, McLauchlan L, Kearnes M. Navigating the grey: experiences of incremental cannabis reform in Australia. Drug Alcohol Rev. 2022 Nov;41(7):1621-9. doi: 10.1111/dar.13518
Mellor R, Lancaster K, Ritter A. Examining untreated and treated alcohol problem resolution in an Australian online survey sample. Drug Alcohol Rev. 2021 Sep;40(6):1037-46. doi: 10.1111/dar.13257
Nagar S, Patel J, Stanford RH. Characteristics and health care resource use of subjects with COPD in the year before initiating LAMA monotherapy or LAMA+LABA combination therapy: a U.S. database study. Manag Care. 2018 May;27(5):40-7.
Meyers J, Candrilli S, Allen R, Manjunath R, Calloway M. Health care resource utilization and costs associated with restless legs syndrome among managed care enrollees treated with dopamine agonists. Manag Care. 2012 Oct 1;21(10):44-51.
Dalal AA, Candrilli SD, Davis KL. Outcomes and costs associated with initial maintenance therapy with fluticasone propionate-salmeterol xinafoate 250 ?g/50 ?g combination versus tiotropium in commercially insured patients with copd. Manag Care. 2011 Aug 1;20(8):46-55.
Iyer S, Davis KL, Candrilli S. Opioid use patterns and health care resource utilization in patients prescribed opioid therapy with and without constipation. Manag Care. 2010 Mar 1;19(3):44-51.